Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Affinity Asset Advisors LLC

Key Points

• Affinity Asset Advisors LLC increased its stake in Xenon Pharmaceuticals by 14.4% during Q1, making it the largest holding of the firm, valued at approximately $44.56 million.
• Institutional investors own around 95.45% of Xenon Pharmaceuticals, reflecting significant interest and investment in the company.
• Xenon Pharmaceuticals reported an earnings miss for the last quarter, with a loss of ($1.07) per share, slightly worse than the consensus estimate of ($1.03).

Affinity Asset Advisors LLC boosted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 14.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,328,175 shares of the biopharmaceutical company's stock after purchasing an additional 166,938 shares during the quarter. Xenon Pharmaceuticals accounts for about 4.3% of Affinity Asset Advisors LLC's portfolio, making the stock its largest holding. Affinity Asset Advisors LLC owned approximately 1.73% of Xenon Pharmaceuticals worth $44,560,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Xenon Pharmaceuticals during the 1st quarter valued at approximately $30,000. GF Fund Management CO. LTD. bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $63,000. Quarry LP purchased a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $78,000. Vident Advisory LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth approximately $212,000. Finally, Tema Etfs LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at $240,000. 95.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada lowered their price target on Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Wedbush upped their price target on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an "outperform" rating in a research report on Tuesday, August 12th. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, August 12th. HC Wainwright reissued a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Finally, Wall Street Zen lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Eleven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $53.20.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $38.14 on Tuesday. The stock has a 50 day moving average price of $33.28 and a 200-day moving average price of $33.90. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00. The company has a market capitalization of $2.94 billion, a P/E ratio of -10.74 and a beta of 1.16.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter in the prior year, the firm posted ($0.75) earnings per share. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.